The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …

Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …

Current immunotherapies yield remarkable clinical outcomes by boosting the power of host
immunity in cancer cell elimination and viral clearance. However, after prolonged antigen …

Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Increasing clinical evidence has demonstrated that the deletion or mutation of tumor
suppressor genes such as the gene-encoding phosphatase and tensin homolog deleted on …

Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer,.
Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and …

Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established
immune regulatory receptor. However, pre-clinical investigations indicated more …

Transcriptomic signatures designed to predict melanoma patient responses to PD-1
blockade have been reported but rarely validated. We now show that intra-patient …